ReviewJournal of immunology research2018
The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases.
Review in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Effects of physical exercise on the functionality of human nucleotidases: A systematic review.Physiological reports · 2022Pooled it
- Purinergic modulation in Parkinson's disease: the dual role of istradefylline in motor and cognitive outcomes.Purinergic signalling · 2026Review
- Synthesis, biological evaluation and molecular docking studies of N-propylsulfonyl indole-linked hydrazinecarbothioamides as selective ecto-5'-nucleotidase and NTPDase inhibitors.Scientific reports · 2026Article
- Purinergic system dysregulation and depression: The neuroinflammatory impact of silica nanoparticles.Environmental analysis, health and toxicology · 2025Article
- Attenuation of PI3K/AKT signaling pathway byBiochemistry and biophysics reports · 2024Article
- Ferulic acid mitigates diabetic cardiomyopathy via modulation of metabolic abnormalities in cardiac tissues of diabetic rats.Fundamental & clinical pharmacology · 2023Article
- High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.Journal of molecular medicine (Berlin, Germany) · 2022Article
- Novel possibility for cutaneous melanoma treatment by means of rosmarinic acid action on purinergic signaling.Purinergic signalling · 2022Review
- Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.International immunopharmacology · 2021Review
- Ectonucleotidases in Inflammation, Immunity, and Cancer.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Epigenome-wide association study of level and change in cognitive abilities from midlife through late life.Clinical epigenetics · 2021Article
- Article
- Purinergic signaling and tumor microenvironment in cervical Cancer.Purinergic signalling · 2020Review
- Functionalized Oxoindolin Hydrazine Carbothioamide Derivatives as Highly Potent Inhibitors of Nucleoside Triphosphate Diphosphohydrolases.Frontiers in pharmacology · 2020Article
- Rutin alleviates cadmium-induced neurotoxicity in Wistar rats: involvement of modulation of nucleotide-degrading enzymes and monoamine oxidase.Metabolic brain disease · 2019Article
- Purinergic Signaling in the Vertebrate Olfactory System.Frontiers in cellular neuroscience · 2019Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidences show that purinergic signaling is involved in processes associated with health and disease, including noncommunicable, neurological, and degenerative diseases. These diseases strike from children to elderly and are generally characterized by progressive deterioration of cells, eventually leading to tissue or organ degeneration. These pathological conditions can be associated with disturbance in the signaling mediated by nucleotides and nucleosides of adenine, in expression or activity of extracellular ectonucleotidases and in activation of P2X and P2Y receptors. Among the best known of these diseases are atherosclerosis, hypertension, cancer, epilepsy, Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). The currently available treatments present limited effectiveness and are mostly palliative. This review aims to present the role of purinergic signaling highlighting the ectonucleotidases E-NTPDase, E-NPP, E-5'-nucleotidase, and adenosine deaminase in noncommunicable, neurological, and degenerative diseases associated with the cardiovascular and central nervous systems and cancer. In conclusion, changes in the activity of ectonucleotidases were verified in all reviewed diseases. Although the role of ectonucleotidases still remains to be further investigated, evidences reviewed here can contribute to a better understanding of the molecular mechanisms of highly complex diseases, which majorly impact on patients' quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.